PofoliaShared via Pofolia

Journal of the American Heart Association· 2026Q1

Machine‐Learning Prediction of Tumor Comorbidity and Cancer‐Associated Mortality in Patients With Coronary Heart Disease: A 2‐Stage Modeling Study

Wei Zheng, Hongsen Cai, Yahui Li, Man Huang et al.

Short summary

Two machine-learning models predict tumor risk (AUC=0.935) and cancer-associated mortality (AUC=0.965) in coronary heart disease (CHD) patients, with strong performance on external validation.

AI-generated from the title and abstract; the full text is not read.

Key points

  • Developed two machine-learning models for predicting tumor risk and cancer-associated mortality in CHD patients.
  • Extreme gradient boosting model achieved AUC=0.935 for tumor risk prediction.
  • Light gradient boosting machine model achieved AUC=0.965 for in-hospital mortality prediction.
  • Models showed good performance in external validation, indicating generalizability.
  • An online prediction platform was implemented to assist clinical decision-making.

AI-generated from the title and abstract; the full text is not read.

Abstract

Background Coronary heart disease (CHD) with concomitant tumors is increasingly prevalent and is associated with a higher mortality. We aimed to develop 2 predictive models to enable early identification of tumor risk in patients with CHD and mortality risk in those with CHD and cancer. Methods We analyzed 134 141 patients with CHD treated at Tongji Hospital (Huazhong University of Science and Technology, Wuhan, Hubei, China) during 2001 to 2023. Data collected from the First Hospital of Peking University (Beijing, China) were used for external validation. We developed and evaluated 6 machine learning models (extreme gradient boosting, light gradient boosting machine, random forest, neural network, decision tree, and logistic regression). Model explainability was improved using Shapley additive explanation, and an online prediction platform was subsequently implemented. Results For the model of predicting tumor risk in patients with CHD, extreme gradient boosting showed the best performance in the test set (area under the receiver operating characteristic curve =0.935), achieving the lowest Brier score (0.080). Its sensitivity, accuracy, and F1 score were 0.740, 0.882, and 0.751, respectively. Meanwhile, light gradient boosting machine performed well for in‐hospital mortality prediction in the test set (area under the receiver operating characteristic curve =0.965), achieving the lowest Brier score (0.019), and the highest sensitivity (0.677), and F1 score (0.599). The 2 models also showed good performance in the external validation, suggesting a degree of generalizability. Conclusions We constructed 2 predictive models to assess the risk of tumor and cancer‐associated mortality in patients with CHD. The web platform assists clinicians in decision‐making and patient management.

The authors' abstract, as published at the source. Journal of the American Heart Association, 2026 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Field: Health Information Management

Health Information ManagementHealth Professions